Materials and methods for diagnosis and treatment of Alzheimer's disease

A method for treating Alzheimer's disease in a subject, comprising:

• a) assaying a sample obtained from the subject for the biomarkers of a biomarker panel comprising:
• i) a phosphoglucomutase 1 comprising the amino acid sequence of SEQ ID NO:1 or an isoform, variant or fragment thereof;
• ii) a thymosin beta-4 comprising the amino acid sequence of SEQ ID NO:2 or a variant or fragment thereof;
• and
• iii) at least one biomarker selected from:
• 1) a ubiquitin carboxy-terminal hydrolase L1 which comprises the amino acid sequence of SEQ ID NO:4 or an isoform, variant, or fragment thereof;
• 2) a vitamin D binding protein which comprises the amino acid sequence of SEQ ID NO:
• 5 or an isoform, variant, or fragment thereof;
• or 3) at least two or more biomarkers selected from the group consisting of:
• Dynactin subunit 1, Cofilin-1, Peroxiredoxin-1, MARCKS-related protein, Moesin, Actin, Protein TMSB4XP4, ApoE, Gelsolin, Secretogranin, Albumin and complement proteins;
• b) measuring in the sample a concentration or an amount of each of the selected biomarkers of the biomarker panel;
• c) determining whether the subject has Alzheimer's disease by comparing the concentration or the amount of each of the selected biomarkers in the sample with reference concentrations or amounts of each of the biomarkers;
• and
• d) administering to the subject an Alzheimer's disease treatment selected from the group consisting of memantine, galantamine, rivastigmine, donepezil, solanezumab, an 5HT5 antagonist, and any combination thereof;
• wherein the sample is selected from the group consisting of cerebrospinal fluid (CSF), blood, plasma, serum, saliva, urine, tissue, and any combination thereof.